Wilmington, Massachusetts-based Charles River Laboratories International, Inc. (CRL) provides drug discovery, non-clinical development, and safety testing services. Valued at $9.5 billion by market cap, the company offers animal research models in research and development for new drugs, devices, and therapies, serving pharmaceutical and biotechnology companies, hospitals, and academic institutions worldwide.

Charles River Laboratories International, Inc. CRL has entered into an agreement with H. Lundbeck A/S (Lundbeck) — a Denmark-based global pharmaceutical company focused on neurological and psychiatric disorders. The collaboration will use Logica, an offering from Charles River and Valo Health, to advance Lundbeck’s research into critical brain diseases. To make a meaningful impact on neurological diseases today, Lundbeck is prioritizing...

Fintel reports that on January 22, 2025, William Blair downgraded their outlook for Charles River Laboratories International (NYSE:CRL) from Outperform to Market Perform. Analyst Price Forecast Suggests 29.68% Upside As of December 23, 2024, the average one-year price target for Charles River Laboratories International is $220.21/share. The forecasts range from a low of $172.71 to a high of $272.17. The average price target represents an...

Up to 96 days are now set for total shutdowns, another 54 for "partial closures" in a bit to prepare for the CRL opening, Simeon Brown says.

Shares of Atara Biotherapeutics ATRA plunged 40.5% on Thursday after the FDA issued a complete response letter (CRL) against the company’s biologics license application (BLA) seeking approval of lead product candidate, tabelecleucel (tab-cel), for the treatment of Epstein-Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) in adult and pediatric patients aged two years and older. The intended patient population includes...